These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
56 related articles for article (PubMed ID: 9422853)
1. Growth factors as a potential new treatment for ischemic heart disease. Bauters C Clin Cardiol; 1997 Nov; 20(11 Suppl 2):II-52-7. PubMed ID: 9422853 [TBL] [Abstract][Full Text] [Related]
2. Growth factors and endothelial dysfunction. Bauters C; Six I; Meurice T; Van Belle E Drugs; 1999; 59 Spec No():11-5. PubMed ID: 10548387 [TBL] [Abstract][Full Text] [Related]
3. Growth factors and endothelial dysfunction. Bauters C; Six I; Meurice T; Van Belle E Drugs; 1999; 58 Spec No 1():11-5. PubMed ID: 10526953 [TBL] [Abstract][Full Text] [Related]
4. Intracavernosal injections of vascular endothelial growth factor protects endothelial dependent corpora cavernosal smooth muscle relaxation in the hypercholesterolemic rabbit: a preliminary study. Henry GD; Byrne R; Hunyh TT; Abraham V; Annex BH; Hagen PO; Donatucci CF Int J Impot Res; 2000 Dec; 12(6):334-9. PubMed ID: 11416837 [TBL] [Abstract][Full Text] [Related]
5. Restoration of coronary collateral growth in the Zucker obese rat: impact of VEGF and ecSOD. Hattan N; Chilian WM; Park F; Rocic P Basic Res Cardiol; 2007 May; 102(3):217-23. PubMed ID: 17323199 [TBL] [Abstract][Full Text] [Related]
6. Local delivery of synthetic prostacycline agonist augments collateral growth and improves cardiac function in a swine chronic cardiac ischemia model. Iwata H; Nakamura K; Sumi M; Ninomiya M; Sakai Y; Hirata Y; Akaike M; Igarashi T; Takamoto S; Nagai R; Sata M Life Sci; 2009 Jul; 85(5-6):255-61. PubMed ID: 19527738 [TBL] [Abstract][Full Text] [Related]
11. Myocardial VEGF expression after cardiopulmonary bypass and cardioplegia. Tofukuji M; Metais C; Li J; Franklin A; Simons M; Sellke FW Circulation; 1998 Nov; 98(19 Suppl):II242-6; discussion II247-8. PubMed ID: 9852909 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic angiogenesis for ischemic syndromes. Weisz A; Koren B; Fischer L; Lewis BS; Flugelman MY Isr Med Assoc J; 2000 Jul; 2 Suppl():52-7. PubMed ID: 10909418 [TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897 [TBL] [Abstract][Full Text] [Related]
14. The coronary endothelium: a target for vascular endothelial growth factor. Human coronary artery endothelial cells express functional receptors for vascular endothelial growth factor in vitro and in vivo. Kranz A; Mayr U; Frank H; Waltenberger J Lab Invest; 1999 Aug; 79(8):985-91. PubMed ID: 10462036 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of the cardiac angiogenic response to surgical FGF-2 therapy in a Swine endothelial dysfunction model. Ruel M; Wu GF; Khan TA; Voisine P; Bianchi C; Li J; Li J; Laham RJ; Sellke FW Circulation; 2003 Sep; 108 Suppl 1():II335-40. PubMed ID: 12970256 [TBL] [Abstract][Full Text] [Related]